Israeli startup Ibex Medical Analytics today announced the first use of its artificial intelligence (AI) solution in Switzerland, helping pathologists with routine cancer diagnosis.
The healthcare provider Kantonsspital Baselland (KSBL) will use the AI-supported Galen platform and help pathologists improve the accuracy and efficiency of primary cancer diagnosis.
The hospital offers histological and molecular integrative cancer diagnostics and individual care for tumor patients.
KSBL pathologists will use the Galen platform to streamline workflows and improve accuracy during primary diagnosis through automated case prioritization, cancer heatmaps, grading and other productivity-enhancing tools.
Ibex’s Galen platform is CE marked for the detection of breast and prostate cancer across multiple workflows.
WHY IT IS IMPORTANT
An increase in cancer prevalence and advances in personalized medicine have led to increased diagnostic complexity that significantly increases the workload of pathologists.
As pathology labs move to digital solutions, pathologists can implement AI-enhanced workflows to improve the quality and efficiency of cancer diagnosis, resulting in better patient care.
THE GREATER CONTEXT
Earlier this year, Ibex announced a $ 38 million Series B funding round to expand its clinical use in North America and Europe.
Meanwhile, Dutch healthcare technology company Royal Philips recently unveiled its new digital pathology platform, IntelliSite, which allegedly uses “advanced algorithms” to help pathologists diagnose and create treatment pathways.
In addition, researchers from the Charité University Clinic Berlin, the Technical University Berlin and the University of Oslo announced the development of a new tissue section analysis system for diagnosing breast cancer based on AI at the beginning of the year. The system facilitates the detection of pathological changes in microscopic images.
ON THE RECORD
Kirsten Mertz MD, Professor of Pathology at KSBL, said: “A timely diagnosis with the highest quality is a cornerstone of cancer care at the Canton Hospital in Bselland, and we strive to continuously improve the technology and processes in our laboratory.
“We are among the pioneers in the introduction of digital pathology in Switzerland and are particularly proud to be the first hospital in the country to introduce AI in pathology. We have been impressed with the performance Ibex’s AI technology has shown in multiple clinical trials in Europe and the US and look forward to getting hands-on experience working with its solution and examining how it can help improve the Can contribute to patient care. “
Stuart Shand, Chief Commercial Officer at Ibex Medical Analytics, said, “We are delighted to be working with KSBL and enabling their pathologists to use cutting-edge AI-powered solutions to more accurately detect cancer and improve the quality and efficiency of diagnosis.
“With this cooperation, KSBL is setting a new standard in the quality of cancer treatment and proving its leadership role and commitment to its patients by using an advanced AI solution at the clinical level to ensure the best possible results. Artificial intelligence and digital pathology technologies are becoming an integral part of cancer treatment programs, and their adoption is a vision shared by both KSBL and Ibex. “